Developer docs
API playgroundTry for free, no card

Search company profiles

Vaxxel

Full company profile

uuid0003ti1

Namestring
Vaxxel
Legal namestring
VAXXEL
Websiteurl
vaxxel.fr
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Vaxxel is a French preclinical-stage biotechnology company developing a proprietary live-attenuated viral vaccine platform branded METAVAC®. Founded in 2019 and headquartered in Villeurbanne (Auvergne-Rhône-Alpes), the company is built around an HMPV-based vaccine vector using the clinical strain C-85473, attenuated through non-reversible deletion of the SH gene. The platform is described as versatile and supports the inclusion of additional respiratory virus antigens, enabling multivalent candidates.

The lead asset, METAVAC® RSV-HMPV, is a bivalent intranasal live-attenuated vaccine designed to protect against both Respiratory Syncytial Virus (RSV) and human Metapneumovirus (HMPV), the two leading causes of bronchiolitis and viral pneumonia in young children and older adults. The candidate is produced on a GMP-grade Vero cell line, has demonstrated preclinical protection against lethal HMPV and RSV challenges in mice and (independently, via an NIAID-funded study) in cotton rats, with six-month stability at 4°C and confirmed genomic stability after ten passages. Preclinical results have been published twice in npj Vaccines (2024 and 2025), and the company is raising €8 million to enter Phase I clinical trials planned for Q3 2025.

Vaxxel is pre-revenue with no commercial product and operates a licensing-oriented business model targeting two patient populations: children under 5 (46 million addressable in EU+US) and adults over 65 (151 million addressable in EU+US). The company monetizes through a planned one-time license / vaccine product sales model once regulatory approval is secured. To date it has raised €1.2 million in seed funding (March 2022) from BpiFrance, Angels Santé, Femmes Business Angels, family offices, and individual investors, and relies on an academic-industrial collaboration network spanning Université Laval, Université Claude Bernard, INSERM, NIAID/NIH, and Sigmovir Biosystems. Leadership combines executives with prior vaccine-industry experience at Pfizer, Sanofi Pasteur, Chiron Vaccines, Baxter, and Merck Serono.

Short descriptiontext

Vaxxel is a French preclinical-stage biotech developing the proprietary METAVAC® HMPV-based live-attenuated vaccine platform. Its lead candidate, METAVAC® RSV-HMPV, is a bivalent intranasal vaccine targeting respiratory syncytial virus and human metapneumovirus in children and older adults.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersVilleurbanne, France
HQ citystring
Villeurbanne
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
intranasal vaccines, live-attenuated vaccines, RSV vaccine, HMPV vaccine, respiratory virus vaccines
Industry2 codes
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Viral Vaccines
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Vaccine Product Sales
TypeOne Time License
Description

Pre-revenue company. Planned revenue from sales of METAVAC® RSV-HMPV bivalent intranasal vaccine targeting children and older adults against RSV and HMPV infections. Target market size >$5bn with expected peak sales of 1.7m€.

vaxxel.fr
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Metavac®
Description

Proprietary viral vaccine platform based on HMPV strain C-85473 with non-reversible functional attenuation through SH gene deletion

vaxxel.fr
+1 more record
Core offering1 text field

Vaxxel is a preclinical-stage French biotech developing intranasal live-attenuated vaccine candidates built on its proprietary METAVAC® platform. Its lead candidate, METAVAC® RSV-HMPV, is a bivalent needle-free vaccine designed to protect against both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) for children under 5 and adults over 65. The vaccine is produced on a GMP-grade Vero cell line and is advancing toward Phase I clinical trials.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Preclinical efficacy validated in two independent animal models (mice and cotton rats) with full protection against hMPV and RSV
+3 more records
Product overview1 text field

Vaxxel is a French biotech company developing a vaccine pipeline centered around its proprietary METAVAC® live-attenuated viral vaccine platform. The lead candidate is Metavac® RSV-HMPV, a bivalent intranasal vaccine designed to protect against both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV). The vaccine candidate has demonstrated preclinical proof-of-concept in animal models and is advancing toward Phase I clinical trials, with a target market exceeding $5 billion covering children and older adults in the EU and US.

Product and service1 record
1METAVAC® RSV-HMPV
CategoryViral vaccines
Description

A bivalent intranasal live-attenuated vaccine candidate based on the METAVAC® platform, designed to protect against both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) — the leading causes of bronchiolitis and viral pneumonia. Produced on a GMP-grade Vero cell line with needle-free intranasal administration, targeting children under 5 and adults over 65 in the EU and US.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Contract research organization that independently performed in vivo testing in cotton rats for Metavac®-RSV efficacy validation. Testing was funded by NIAID under contract #HHSN272201700028I/75N93023F00001.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in RESPIVIR France-Canada International Research Laboratory. Contributed to preclinical development and validation of Metavac®-RSV vaccine candidate.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partner in RESPIVIR France-Canada International Research Laboratory. Home to VirPath University lab and Virnext research group that contributed to vaccine development.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

French national institute for health and medical research. Dr. Manuel Rosa-Calatrava serves as Research Director at INSERM and Deputy head of VirPath University lab.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Bavarian Nordic is developing an RSV vaccine candidate and has scaled commercial vaccine manufacturing capabilities. It is comparable as an emerging-to-mid-stage vaccine developer focused on respiratory viral targets with similar scale to Vaxxel's post-Phase I profile.

TypeBroad incumbent
Description

Novavax is developing a recombinant RSV vaccine (ResVax historically) targeting maternal and pediatric populations. Comparable as an established vaccine developer pursuing RSV with a different platform (protein nanoparticle vs Vaxxel's LAV).

TypeBroad incumbent
Description

Merck (via legacy Merck Serono where Vaxxel's CEO Denis Cavert was BU Director) is a major vaccine player with growing respiratory franchise interest. As a Big Pharma incumbent with deep RSV/vaccine R&D, it is comparable as a likely strategic counterparty.

TypeEmerging player
Description

Codagenix develops live-attenuated viral vaccines using codon-deoptimization technology, with RSV and other respiratory virus candidates. Highly comparable platform-level technology alignment with Vaxxel's live-attenuated viral vaccine approach.

TypeBroad incumbent
Description

Janssen has historically pursued RSV vaccine development through non-replicating adenovirus platforms and is a relevant incumbent comparable in target indication and major-pharma R&D depth, though currently less active in RSV than Pfizer/GSK/Moderna.

TypeDirect peer
Description

Moderna is developing mRNA-1083, a bivalent RSV+HMPV vaccine candidate in clinical trials — directly comparable to Vaxxel's METAVAC®-RSV-HMPV in target indication, antigen combination, and population. It is the most direct competitive threat to Vaxxel's bivalent thesis, though using mRNA rather than a live-attenuated platform.

TypeBroad incumbent
Description

Pfizer markets Abrysvo, the first approved RSV vaccine for older adults and maternal immunization, and previously acquired ReViral for RSV antivirals. Pfizer is a direct competitor in the RSV vaccine space and a likely potential acquirer of Vaxxel given Bernard Fritzell's prior Pfizer role.

TypeBroad incumbent
Description

Sanofi is developing competing RSV vaccine candidates and has deep vaccine franchise via Sanofi Pasteur. Several Vaxxel team members (Bernard Fritzell, Bernard Fanget) have prior Sanofi Pasteur leadership, making Sanofi a logical strategic acquirer for Vaxxel.

TypeDirect peer
Description

Meissa Vaccines develops intranasal live-attenuated RSV vaccine candidates, sharing Vaxxel's intranasal LAV approach and pediatric RSV focus. Closely comparable in mechanism, delivery route, and target indication, making it the most direct intranasal-LAV peer.

10GSK
TypeBroad incumbent
Description

GSK markets Arexvy, the first approved RSV vaccine for older adults, and acquired Affinivax to expand its respiratory vaccine portfolio. GSK is a major competitor for RSV and a potential strategic acquirer for HMPV exposure.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vaxxel

Viral Vaccinesvaxxel.fr

Vaxxel is a French preclinical-stage biotech developing the proprietary METAVAC® HMPV-based live-attenuated vaccine platform. Its lead candidate, METAVAC® RSV-HMPV, is a bivalent intranasal vaccine targeting respiratory syncytial virus and human metapneumovirus in children and older adults.

What Vaxxel does

Vaxxel is a French preclinical-stage biotechnology company developing a proprietary live-attenuated viral vaccine platform branded METAVAC®. Founded in 2019 and headquartered in Villeurbanne (Auvergne-Rhône-Alpes), the company is built around an HMPV-based vaccine vector using the clinical strain C-85473, attenuated through non-reversible deletion of the SH gene. The platform is described as versatile and supports the inclusion of additional respiratory virus antigens, enabling multivalent candidates.

The lead asset, METAVAC® RSV-HMPV, is a bivalent intranasal live-attenuated vaccine designed to protect against both Respiratory Syncytial Virus (RSV) and human Metapneumovirus (HMPV), the two leading causes of bronchiolitis and viral pneumonia in young children and older adults. The candidate is produced on a GMP-grade Vero cell line, has demonstrated preclinical protection against lethal HMPV and RSV challenges in mice and (independently, via an NIAID-funded study) in cotton rats, with six-month stability at 4°C and confirmed genomic stability after ten passages. Preclinical results have been published twice in npj Vaccines (2024 and 2025), and the company is raising €8 million to enter Phase I clinical trials planned for Q3 2025.

Vaxxel is pre-revenue with no commercial product and operates a licensing-oriented business model targeting two patient populations: children under 5 (46 million addressable in EU+US) and adults over 65 (151 million addressable in EU+US). The company monetizes through a planned one-time license / vaccine product sales model once regulatory approval is secured. To date it has raised €1.2 million in seed funding (March 2022) from BpiFrance, Angels Santé, Femmes Business Angels, family offices, and individual investors, and relies on an academic-industrial collaboration network spanning Université Laval, Université Claude Bernard, INSERM, NIAID/NIH, and Sigmovir Biosystems. Leadership combines executives with prior vaccine-industry experience at Pfizer, Sanofi Pasteur, Chiron Vaccines, Baxter, and Merck Serono.

Vaxxel firmographics

Firmographics
Name
Vaxxel
Legal name
VAXXEL
Website
https://vaxxel.fr
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Vaxxel is a French preclinical-stage biotech developing the proprietary METAVAC® HMPV-based live-attenuated vaccine platform. Its lead candidate, METAVAC® RSV-HMPV, is a bivalent intranasal vaccine targeting respiratory syncytial virus and human metapneumovirus in children and older adults.
Ownership category
akta.pro rank

Vaxxel industry classification

Industry
Product category
Viral Vaccines
NAICS
Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAA
Prophylactic Human Vaccines (routine, pediatric, adult)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Intranasal vaccines
  • Live-attenuated vaccines
  • RSV vaccine
  • HMPV vaccine
  • Respiratory virus vaccines

Where Vaxxel is headquartered

Location

Headquarters

HQ city
Villeurbanne
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Vaxxel business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain

Revenue model

  1. Vaccine Product Sales: Pre-revenue company. Planned revenue from sales of METAVAC® RSV-HMPV bivalent intranasal vaccine targeting children and older adults against RSV and HMPV infections. Target market size >$5bn with expected peak sales of 1.7m€.

Go-to-market motion1 record

Marketing channels3 records

Vaxxel product offering

Product offering

Core offering

Vaxxel is a preclinical-stage French biotech developing intranasal live-attenuated vaccine candidates built on its proprietary METAVAC® platform. Its lead candidate, METAVAC® RSV-HMPV, is a bivalent needle-free vaccine designed to protect against both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) for children under 5 and adults over 65. The vaccine is produced on a GMP-grade Vero cell line and is advancing toward Phase I clinical trials.

Product overview

Vaxxel is a French biotech company developing a vaccine pipeline centered around its proprietary METAVAC® live-attenuated viral vaccine platform. The lead candidate is Metavac® RSV-HMPV, a bivalent intranasal vaccine designed to protect against both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV). The vaccine candidate has demonstrated preclinical proof-of-concept in animal models and is advancing toward Phase I clinical trials, with a target market exceeding $5 billion covering children and older adults in the EU and US.

Differentiator

Problem solved

Functional benefit

Brands

  • Metavac®: Proprietary viral vaccine platform based on HMPV strain C-85473 with non-reversible functional attenuation through SH gene deletion
  • Metavac®-RSV

Products and services

  • METAVAC® RSV-HMPV A bivalent intranasal live-attenuated vaccine candidate based on the METAVAC® platform, designed to protect against both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) — the leading causes of bronchiolitis and viral pneumonia. Produced on a GMP-grade Vero cell line with needle-free intranasal administration, targeting children under 5 and adults over 65 in the EU and US.

Quantifiable outcome

  • Preclinical efficacy validated in two independent animal models (mice and cotton rats) with full protection against hMPV and RSV
  • +3 more outcomes

Companies that use Vaxxel

Customer profile

Segments2 records

Ideal customer profiles2 records

Vaxxel technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vaxxel partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Sigmovir Biosystems, Inc.coreStrategic or Co-development PartnerContract research organization that independently performed in vivo testing in cotton rats for Metavac®-RSV efficacy validation. Testing was funded by NIAID under contract #HHSN272201700028I/75N93023F00001.
  • Université Laval (Québec, Canada)coreStrategic or Co-development PartnerPartner in RESPIVIR France-Canada International Research Laboratory. Contributed to preclinical development and validation of Metavac®-RSV vaccine candidate.
  • Université Claude Bernard (Lyon, France)coreStrategic or Co-development PartnerPartner in RESPIVIR France-Canada International Research Laboratory. Home to VirPath University lab and Virnext research group that contributed to vaccine development.
  • INSERM (Institut national de la santé et de la recherche médicale)coreStrategic or Co-development PartnerFrench national institute for health and medical research. Dr. Manuel Rosa-Calatrava serves as Research Director at INSERM and Deputy head of VirPath University lab.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Vaxxel competitors and assessment

Company assessment

Emerging players

  • Bavarian Nordic: Bavarian Nordic is developing an RSV vaccine candidate and has scaled commercial vaccine manufacturing capabilities. It is comparable as an emerging-to-mid-stage vaccine developer focused on respiratory viral targets with similar scale to Vaxxel's post-Phase I profile.
  • Codagenix: Codagenix develops live-attenuated viral vaccines using codon-deoptimization technology, with RSV and other respiratory virus candidates. Highly comparable platform-level technology alignment with Vaxxel's live-attenuated viral vaccine approach.

Broad incumbents

  • Novavax: Novavax is developing a recombinant RSV vaccine (ResVax historically) targeting maternal and pediatric populations. Comparable as an established vaccine developer pursuing RSV with a different platform (protein nanoparticle vs Vaxxel's LAV).
  • Merck & Co. Merck (via legacy Merck Serono where Vaxxel's CEO Denis Cavert was BU Director) is a major vaccine player with growing respiratory franchise interest. As a Big Pharma incumbent with deep RSV/vaccine R&D, it is comparable as a likely strategic counterparty.
  • Johnson & Johnson (Janssen): Janssen has historically pursued RSV vaccine development through non-replicating adenovirus platforms and is a relevant incumbent comparable in target indication and major-pharma R&D depth, though currently less active in RSV than Pfizer/GSK/Moderna.
  • Pfizer: Pfizer markets Abrysvo, the first approved RSV vaccine for older adults and maternal immunization, and previously acquired ReViral for RSV antivirals. Pfizer is a direct competitor in the RSV vaccine space and a likely potential acquirer of Vaxxel given Bernard Fritzell's prior Pfizer role.
  • Sanofi: Sanofi is developing competing RSV vaccine candidates and has deep vaccine franchise via Sanofi Pasteur. Several Vaxxel team members (Bernard Fritzell, Bernard Fanget) have prior Sanofi Pasteur leadership, making Sanofi a logical strategic acquirer for Vaxxel.
  • GSK: GSK markets Arexvy, the first approved RSV vaccine for older adults, and acquired Affinivax to expand its respiratory vaccine portfolio. GSK is a major competitor for RSV and a potential strategic acquirer for HMPV exposure.

Direct peers

  • Moderna: Moderna is developing mRNA-1083, a bivalent RSV+HMPV vaccine candidate in clinical trials — directly comparable to Vaxxel's METAVAC®-RSV-HMPV in target indication, antigen combination, and population. It is the most direct competitive threat to Vaxxel's bivalent thesis, though using mRNA rather than a live-attenuated platform.
  • Meissa Vaccines: Meissa Vaccines develops intranasal live-attenuated RSV vaccine candidates, sharing Vaxxel's intranasal LAV approach and pediatric RSV focus. Closely comparable in mechanism, delivery route, and target indication, making it the most direct intranasal-LAV peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

Vaxxel social profiles

Digital presence

Vaxxel financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vaxxel leadership team

Management profile

Number of profiles

Profiles8 records

Vaxxel funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vaxxel M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vaxxel

What does Vaxxel do?

Vaxxel is a preclinical-stage French biotech developing intranasal live-attenuated vaccine candidates built on its proprietary METAVAC® platform. Its lead candidate, METAVAC® RSV-HMPV, is a bivalent needle-free vaccine designed to protect against both Respiratory Syncytial Virus (RSV) and Human Metapneumovirus (HMPV) for children under 5 and adults over 65. The vaccine is produced on a GMP-grade Vero cell line and is advancing toward Phase I clinical trials.

Is Vaxxel a public or private company?

Vaxxel is a private company. It is classified as venture growth investor backed and is currently operating.

When was Vaxxel founded?

Vaxxel was founded in 2019. It employs 1 to 10 people.

Where is Vaxxel based?

Vaxxel is headquartered in Villeurbanne, France, in the Europe region.

How does Vaxxel make money?

One revenue line is on record: vaccine Product Sales.

Who are Vaxxel's main competitors?

Emerging players on record are Bavarian Nordic and Codagenix. Broad incumbents are Novavax, Merck & Co., Johnson & Johnson (Janssen), Pfizer, Sanofi and GSK. Direct peers are Moderna and Meissa Vaccines.

Does Vaxxel have an API?

No public API is recorded for Vaxxel.

What industry is Vaxxel in?

Vaxxel's product category is Viral Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAA, Prophylactic Human Vaccines (routine, pediatric, adult). Its NAICS code is 5417 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals